Editorial: fenofibrate as second-line therapy in high risk PBC - more answers or more questions?

被引：4

作者：

Jones, D. E. J. ^{[1
]}

Hansen, B. E. ^{[2
]}

机构：

[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] Erasmus MC, Univ Med Ctr Rotterdam, Epidemiol & Biostat, Rotterdam, Netherlands

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2016年 / 43卷 / 05期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1111/apt.13507

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：648 / 649

页数：2

共 8 条

[1] The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis [J].

Carbone, Marco ;

Sharp, Stephen J. ;

Flack, Steve ;

Paximadas, Dimitrios ;

Spiess, Kelly ;

Adgey, Carolyn ;

Griffiths, Laura ;

Lim, Reyna ;

Trembling, Paul ;

Williamson, Kate ;

Wareham, Nick J. ;

Aldersley, Mark ;

Bathgate, Andrew ;

Burroughs, Andrew K. ;

Heneghan, Michael A. ;

Neuberger, James M. ;

Thorburn, Douglas ;

Hirschfield, Gideon M. ;

Cordell, Heather J. ;

Alexander, Graeme J. ;

Jones, David E. J. ;

Sandford, Richard N. ;

Mells, George F. .

HEPATOLOGY, 2016, 63 (03) :930-950

[2] Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes [J].

Cheung, A. C. ;

Lapointe-Shaw, L. ;

Kowgier, M. ;

Meza-Cardona, J. ;

Hirschfield, G. M. ;

Janssen, H. L. A. ;

Feld, J. J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :283-293

[3] Novel therapeutic targets in primary biliary cirrhosis [J].

Dyson, Jessica K. ;

Hirschfield, Gideon M. ;

Adams, David H. ;

Beuers, Ulrich ;

Mann, Derek A. ;

Lindor, Keith D. ;

Jones, David E. J. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2015, 12 (03) :147-158

[4] Unmet clinical need in autoimmune liver diseases [J].

Dyson, Jessica K. ;

Webb, Gwilym ;

Hirschfield, Gideon M. ;

Lohse, Ansgar ;

Beuers, Ulrich ;

Lindor, Keith ;

Jones, David E. J. .

JOURNAL OF HEPATOLOGY, 2015, 62 (01) :208-218

[5] Fibrates and cholestasis [J].

Ghonem, Nisanne S. ;

Assis, David N. ;

Boyer, James L. .

HEPATOLOGY, 2015, 62 (02) :635-643

[6] Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis [J].

Grigorian, Alla Y. ;

Mardini, Houssam E. ;

Corpechot, Christophe ;

Poupon, Raoul ;

Levy, Cynthia .

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 (03) :296-306

[7] Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis [J].

Kumagi, Teru ;

Guindi, Maha ;

Fischer, Sandra E. ;

Arenovich, Tamara ;

Abdalian, Rupert ;

Coltescu, Catalina ;

Heathcote, E. Jenny ;

Hirschfield, Gideon M. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (10) :2186-2194

[8] Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis [J].

Zhang, Yan ;

Li, Sainan ;

He, Lei ;

Wang, Fan ;

Chen, Kan ;

Li, Jingjing ;

Liu, Tong ;

Zheng, Yuanyuan ;

Wang, Jianrong ;

Lu, Wenxia ;

Zhou, Yuqing ;

Yin, Qin ;

Xia, Yujing ;

Zhou, Yingqun ;

Lu, Jie ;

Guo, Chuanyong .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :2757-2766

← 1 →